Compounded Testosterone Troches TO OPTIMIZE HEALTH AND THE TESTOSTERONE CONTROVERSY

Area of Science:

• Endocrinology
• Men's Health
• Gerontology

Background:

• Aging men experience declining testosterone levels (andropause), leading to adverse effects like reduced well-being, sarcopenia, cardiovascular risks, and bone loss.
• Testosterone replacement therapy (TRT) is increasingly sought by men, but concerns exist regarding potential cardiovascular events.
• A significant body of evidence suggests properly administered TRT, with controlled estradiol and dihydrotestosterone, does not increase myocardial infarction risk.

Purpose of the Study:

• To review the literature on testosterone replacement therapy (TRT) and its cardiovascular safety in aging men.
• To clarify the controversy surrounding TRT, particularly concerning the role of estradiol and dihydrotestosterone control.
• To highlight the benefits and cost-effectiveness of current TRT protocols, including compounded testosterone troches.

Main Methods:

• Extensive literature review of clinical studies on testosterone replacement therapy.
• Analysis of studies focusing on TRT protocols that control estradiol and dihydrotestosterone levels.
• Examination of the components and cost-effectiveness of modern TRT, including compounded testosterone troches and hormone inhibitors.

Main Results:

• The majority of clinical studies indicate that properly administered TRT, with controlled estradiol and dihydrotestosterone, shows no adverse effects on myocardial infarction risk.
• Current state-of-the-art TRT involves compounded testosterone troches with aromatase inhibitors (e.g., Anastrozole) and 5α-reductase inhibitors (e.g., Dutasteride/Finasteride).
• Compounded testosterone troches are cost-effective and effectively raise serum testosterone to optimal ranges, yet coverage is often denied.

Conclusions:

• The controversy surrounding TRT safety is largely due to poorly designed studies that failed to control estradiol and dihydrotestosterone levels.
• Properly administered TRT, as outlined by current protocols, is safe and beneficial for aging men with testosterone deficiency.
• The denial of insurance coverage for compounded TRT medications like testosterone troches limits access despite demonstrated health benefits and cost-effectiveness.